Terms: = Ovarian cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Treatment
21 results:
1. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
2. ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
[TBL] [Abstract] [Full Text] [Related]
3. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/gata3 axis.
Wang H; Zhou Y; Zhang S; Qi YA; Wang M
Oncol Res; 2021; 29(4):275-289. PubMed ID: 37303939
[TBL] [Abstract] [Full Text] [Related]
4. An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in ovarian cancer.
Gonzalez-Ochoa E; Oza AM
Clin Cancer Res; 2023 Jul; 29(14):2563-2566. PubMed ID: 37191665
[TBL] [Abstract] [Full Text] [Related]
5. Vorinostat decrease M2 macrophage polarization through ARID1A
Hsieh TH; Hsu CY; Wu CW; Wang SH; Yeh CH; Cheng KH; Tsai EM
Biomed Pharmacother; 2023 May; 161():114500. PubMed ID: 36958195
[TBL] [Abstract] [Full Text] [Related]
6. Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the Clinical Outcome of Early-stage Endometrial cancer Patients Treated With Adjuvant Vaginal Brachytherapy.
Laliscia C; Gadducci A; Coccia N; Mattioni R; Fuentes T; Caretto M; Pistolesi S; Puccini P; Perrone F; Morganti R; Paiar F
Anticancer Res; 2023 Jan; 43(1):149-156. PubMed ID: 36585177
[TBL] [Abstract] [Full Text] [Related]
7. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
Jimenez-Sainz J; Jensen RB
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065235
[TBL] [Abstract] [Full Text] [Related]
8. Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline ovarian Tumors by Integrative Polygenic Analytics.
Chang CM; Li YF; Lin HC; Lu KH; Lin TW; Liu LC; Su KM; Chang CC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921111
[TBL] [Abstract] [Full Text] [Related]
9. 5-AZA-dC induces epigenetic changes associated with modified glycosylation of secreted glycoproteins and increased EMT and migration in chemo-sensitive cancer cells.
Greville G; Llop E; Howard J; Madden SF; Perry AS; Peracaula R; Rudd PM; McCann A; Saldova R
Clin Epigenetics; 2021 Feb; 13(1):34. PubMed ID: 33579350
[TBL] [Abstract] [Full Text] [Related]
10. gata3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract] [Full Text] [Related]
11. Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial cancer.
Alban GM; Buscariollo DL; Cheng T; Pretz J; Krechmer B; Buzurovic I; Singer L; King M; Lee L
Pract Radiat Oncol; 2020; 10(2):95-103. PubMed ID: 31783169
[TBL] [Abstract] [Full Text] [Related]
12. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
[TBL] [Abstract] [Full Text] [Related]
13. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
Na K; Lee JY; Sung JY; Kim GM; Koo JS; Kim HS
Virchows Arch; 2018 Aug; 473(2):165-175. PubMed ID: 29926183
[TBL] [Abstract] [Full Text] [Related]
14. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma.
Jordan SE; Micaily I; Hernandez E; Ferriss JS; Miyamoto CT; Li S; Micaily B
Brachytherapy; 2017; 16(6):1144-1151. PubMed ID: 28958736
[TBL] [Abstract] [Full Text] [Related]
15. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/gata3 axis.
Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
[TBL] [Abstract] [Full Text] [Related]
16. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
Lu SM; Chang-Halpenny C; Hwang-Graziano J
Gynecol Oncol; 2015 Apr; 137(1):28-33. PubMed ID: 25666606
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.
Vargo JA; Boisen MM; Comerci JT; Kim H; Houser CJ; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Huang M; Courtney-Brooks M; Beriwal S
Gynecol Oncol; 2014 Nov; 135(2):190-5. PubMed ID: 25218303
[TBL] [Abstract] [Full Text] [Related]
18. A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer.
Townamchai K; Lee L; Viswanathan AN
Gynecol Oncol; 2012 Nov; 127(2):351-5. PubMed ID: 22850411
[TBL] [Abstract] [Full Text] [Related]
19. Dose volume analysis of radiotherapy for inoperable patients with stage I-II endometrial carcinoma.
Ohkubo Y; Kato S; Kiyohara H; Tsuruoka I; Tamaki T; Noda SE; Ohno T; Nakano T
J Radiat Res; 2011; 52(5):666-73. PubMed ID: 21857147
[TBL] [Abstract] [Full Text] [Related]
20. Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells.
Jiang S; Katayama H; Wang J; Li SA; Hong Y; Radvanyi L; Li JJ; Sen S
Horm Cancer; 2010 Feb; 1(1):11-20. PubMed ID: 21761347
[TBL] [Abstract] [Full Text] [Related]
[Next]
